Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Private equity funds grab smaller slice of M&A deals

Fri, 28th Mar 2014 00:00

By Freya Berry

LONDON, March 28 (Reuters) - Buyout firms are finding itharder to take part in mergers and acquisitions as the lure ofstronger equity markets persuades more funds seeking to exitassets to try their luck with a public share sale or turn tocash-rich corporate buyers.

Private equity-backed mergers and acquisitions (M&A) fell byalmost a third to $55.2 billion from a year ago, Thomson Reutersquarterly data showed on Friday.

European private equity firms accounted for 8 percent of M&Adeals in the year to date, down from 10 percent from the sameperiod last year and the lowest since 2011, although the valueof private equity-backed deals did rise in the region.

"The bottom line is that in many sectors private equity isstruggling to compete with the public markets," said JamesSimpson, Head of Sponsor M&A at UBS. "Assets that wouldnaturally have come to private equity are going to IPO."

The MSCI World Price Index surged 24 percentlast year. That has brought a rash of companies to market asthey seek to capitalise on buoyant public interest, limiting thedeals available for buyout firms.

Private equity firms are also grappling with asset priceinflation.

Valuations have risen, partly due to a scarcity of assets,because of companies turning to IPOs, but also due to a growingamount of undeployed fund capital which leaves private equityfunds paying out more as they hunt for ways to spend cash.

A report by Bain & Company this month found that undeployedcapital, or dry powder, hit $1 trillion at the end of 2013,pushed up by investors seeking returns in a world of lowinterest rates.

"Multiples have gone up," Simpson said. "You have toacclimatise to paying bigger prices, and that takes a bit oftime."

As well as expensive assets, funds are also shying away fromcompetition with huge corporate cashpiles built up since thefinancial crisis.

Last year, GlaxoSmithKline scrapped a plan to sellits drinks businesses Lucozade and Ribena in an auction whichwould have included private equity firms when Japan's SuntoryBeverage & Food muscled in.

"Whilst (investors) would continue to say this is afantastic environment in which to exit businesses, it's actuallystill proving to be a challenging environment in which to deploynew capital," said Alasdair Warren, head of European FinancialSponsors Group at Goldman Sachs.

"The IPO markets are so strong and the multiples are sohigh, that it is very difficult for sponsors to compete."

But despite the squeeze, private equity firms are confidentthat the rush to IPO will not last forever.

"It is likely that the IPO markets will remain open for sometime but how long it will last is hard to tell," said LionelAssant, Senior Managing Director and European Head of PrivateEquity at Blackstone.

"Public markets rightly demand a proven management team anda clear strategy for growth from any company floating."

Goldman Sachs led the global rankings for M&A advisorbanks with a 46.3 percent market share, while JP Morgan was top for European deals with a 32.4 percent market share, thedata showed.

There have been 271 deals in Europe so far, an increase of6.7 percent year-on-year. But the value of transactionsincluding net debt has soared 24 percent to $12.9 billion overthe same period, the data showed. (Editing by Elaine Hardcastle)

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.